Skip to Content

Research and Clinical Trials

Today’s discoveries change tomorrow’s lives. 

The NorthShore Neurological Institute has a strong commitment to research and innovation. As one of the region’s preeminent providers of neurological care, we are actively engaged in clinical trials and other research. We are regularly launching new clinical studies to ensure that the latest diagnostic technology, clinical treatments and surgical techniques are available for our patients; and to understand better the causes of neurological diseases and to develop new methods of predicting and improving neurological outcomes.

Research at the Neurological Institute is multidisciplinary, with neurologists, neurosurgeons, neuroradiologists, neuropsychologists and a large team of research personnel engaged in a wide array of studies, often national and international in scope. Neurological Institute co-Directors are leading some of the most innovative and promising neurological research studies worldwide:

  • Genetic Epidemiology of Parkinson’s Disease Consortium (GEO-PD)— includes 57 sites from 29 countries and 6 continents and from the group’s research, has invented a new method to treat Parkinson’s disease that applies a Nobel Prize-winning technology called RNA interference.
  • DodoNA Project—At NorthShore the DodoNA Project is a study that uses blood samples and our award-winning electronic medical record to discover DNA variations that predict neurological outcomes and that will guide the development of disease-modifying treatments for 11 neurological disorders.
  • Chronic Traumatic Encephalopathy—Dr. Bailes and his collaborators were the first to apply new brain imaging technologies to detect during life chronic traumatic encephalopathy (CTE), a disorder that results from repeated mild traumatic brain injuries (“concussions”).

For a summary of ongoing clinical trials and other research news, please see our Research Updates newsletter.

For immediate access to excellence and expertise, call us toll free at 877.570.7020.